INDIGO

CERTIFICATE OF ANALYSIS

Certificate	IP-COA-CI-261007
Issued	6 October 2026
Status	RELEASED

CJC-1295 + Ipamorelin

Lyophilised blend of two growth hormone secretagogues

BATCH

IP-CI-261003 This is the code printed on your vial.

APPLICABLE STRENGTHS

10 mg

99.05%

RP-HPLC

Specification ≥ 99.0% for every component

ENDOTOXIN

< 0.1 EU/mg

Kinetic chromogenic LAL

STERILITY

No growth

Membrane filtration

ANALYSED

5 October 2026

Batch made 3 October 2026

Full analytical results

TESTS AND SPECIFICATIONS

Appearance

Visual inspection

SPECIFICATION	White to off-white lyophilised powder
RESULT	Conforms
STATUS	PASS

Purity

RP-HPLC, each component separately; the figure shown is the limiting component

SPECIFICATION	≥ 99.0% for every component
RESULT	99.05%
STATUS	PASS

Blend ratio

RP-HPLC, each component quantified against its own reference standard

SPECIFICATION	Each component within ± 5.0% of its declared share
RESULT	50.3% / 49.7%
STATUS	PASS

Related substances

RP-HPLC, any single impurity

SPECIFICATION	≤ 1.0%
RESULT	0.40%
STATUS	PASS

Water content

Karl Fischer titration

SPECIFICATION	≤ 8.0%
RESULT	3.51%
STATUS	PASS

pH, 1% aqueous solution

Potentiometry at 25 °C

SPECIFICATION	4.0 to 7.5
RESULT	5.8
STATUS	PASS

Bacterial endotoxins

Kinetic chromogenic LAL

SPECIFICATION	< 1.0 EU/mg
RESULT	< 0.1 EU/mg
STATUS	PASS

Sterility

Membrane filtration (USP <71>)

SPECIFICATION	No growth
RESULT	No growth
STATUS	PASS

Residual solvents

Headspace GC-FID (USP <467>)

SPECIFICATION	Acetonitrile ≤ 410 ppm, methanol ≤ 3000 ppm, dichloromethane ≤ 600 ppm (ICH Q3C)
RESULT	Conforms
STATUS	PASS

Elemental impurities

ICP-MS (USP <232> and <233>)

SPECIFICATION	Pb ≤ 5, Cd ≤ 2, As ≤ 15, Hg ≤ 3 µg/day (ICH Q3D, parenteral)
RESULT	Conforms
STATUS	PASS

COMPONENTS

A blend is only as pure as its weakest component, so the purity at the top of this certificate is the lowest of the figures below, never an average.

CJC-1295 (no DAC)

DECLARED SHARE	50.0%
PURITY	99.05%
ION	[M+3H]3+
OBSERVED M/Z	1123.61

Ipamorelin

DECLARED SHARE	50.0%
PURITY	99.75%
ION	[M+H]+
OBSERVED M/Z	713.01

CHROMATOGRAM



Reversed-phase trace for this batch. One dominant peak at 16.7 minutes, 99.05% of the total peak area, largest single impurity 0.40%.

STORAGE AND HANDLING

UNOPENED

2 to 8 °C, away from light

LONG TERM

−20 °C, lyophilised, for the stated shelf life

RECONSTITUTED

2 to 8 °C, use within 4 weeks; avoid repeated freeze and thaw

IN TRANSIT

Stable at ambient temperature for up to 30 days

RECONSTITUTE WITH

Bacteriostatic water

THE VIAL THIS COVERS

The label on your vial carries the same batch code as this certificate, `IP-CI-261003`, and the QR goes to the results for it. If the code on the vial is not this one, the certificate for it is on this page under earlier batches.

Sticker shown at its printed size, 40 by 20 mm. Cap colour may vary by batch.

RELEASE

BATCH DATE 3 October 2026	ANALYSIS DATE 5 October 2026
ISSUE DATE 6 October 2026	BEST BEFORE October 2028
RELEASED BY Quality review, Indigo Peptides	DOCUMENT Valid only in its original, unmodified form

Results are taken from the batch testing documentation for this exact batch, supplied with the finished vials and held on file by us. Every value above is for the batch named on this certificate and for no other.

HOLDING AN OLDER VIAL?

IP-CI-260914

PURITY	99.40%
ANALYSED	16 September 2026

If the code on your vial is one of these, it is an earlier batch of ours and these are its results. A result we have published is never removed and never recalculated.